NCT00433459 - Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma | Biotech Hunter

Enrollment

2,134

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

Lymphoma

Interventions

DRUG

cyclophosphamide

drug is used in first line treatment in combination (COPP or COPDAC)

DRUG

dacarbazine

drug is used in first line treatment in combination (COPDAC)

DRUG

prednisolone

drug is used in first line treatment in combination (OEPA, COPP or COPDAC)

DRUG

prednisone

drug is used in first line treatment in combination (OEPA, COPP or COPDAC)

DRUG

procarbazine hydrochloride

drug is used in first line treatment in combination (COPP)

DRUG

vincristine sulfate

drug is used in first line treatment in combination (OEPA, COPP or COPDAC)

RADIATION

fludeoxyglucose F 18

used as a diagnostic marker for metabolically active tumour at staging and response assessment

RADIATION

radiation therapy

part of combination treatment (combined modality between chemo- and radiotherapy)

Trial Locations (2)

D-35385

Universitaetsklinikum Giessen-Marburg, Giessen

EH9 1LF

Royal Hospital for Sick Children, Edinburgh

All Listed Sponsors

collaborator

Deutsche Krebshilfe e.V., Bonn (Germany)

OTHER

collaborator

Euronet Worldwide

OTHER

lead

Christine Mauz-Körholz

OTHER